Medtronic Garners Bilateral Activa Medicare Reimbursement In 33 States
This article was originally published in The Gray Sheet
Executive Summary
Medtronic Neurological President Scott Ward acknowledges that current off-label use of the company's Activa deep brain stimulation device for the bilateral treatment of Parkinson's tremor may dampen sales expectations once FDA approves the indication.
You may also be interested in...
CMS Reviewing Medtronic Activa Reimbursement For Bilateral Indication
The Centers for Medicare & Medicaid Services has initiated a national coverage review of Medtronic's Activa for bilateral brain stimulation in Parkinson's disease patients, but the agency will not reimburse the indication until it is approved by FDA.
CMS Reviewing Medtronic Activa Reimbursement For Bilateral Indication
The Centers for Medicare & Medicaid Services has initiated a national coverage review of Medtronic's Activa for bilateral brain stimulation in Parkinson's disease patients, but the agency will not reimburse the indication until it is approved by FDA.
Medtronic Holding Pat On $480 Mil. Acquisition Offer Spurned By Cyberonics
Medtronic's stalled $480 mil. acquisition bid for Cyberonics may be the first test for President and Chief Operating Officer Arthur Collins as he prepares to assume the top executive post at Medtronic next spring.